Shared Decision Making and the Current Landscape of Checkpoint Inhibitor Therapy in Metastatic NSCLC

Interact with your peers while gaining expert insight on how to best use immune checkpoint inhibitors for the treatment of advanced NSCLC in this 1-hour, expert-led, case-based workshop. The latest clinical data will be highlighted as will guidance on individualizing therapy with input from patients.


  • Clinical guidance on optimal use of immune checkpoint inhibitors for advanced NSCLC
    • Histology agnostic and specific
    • Single-agent and combination therapy
    • First-line and progressive metastatic NSCLC
    • Immune-related adverse event management
  • Principles of shared decision making and practical application in NSCLC care
    • Suggestions for individualizing therapy with input from patients
    • Resources on shared decision making for patients


Date / Time
Event Details


Program Director
Howard West, MD

Associate Clinical Professor
City of Hope Comprehensive Cancer Center
Duarte, California

Helena Yu, MD

Assistant Attending 
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ ability to optimize patient outcomes by facilitating activities that support a shared decision making approach between clinicians and patients and that accelerate the awareness and integration of evidence-based therapeutic approaches using immune checkpoint inhibitors in the treatment of non-small-cell lung cancer.

Target Audience 
This program is intended for physicians, nurses, pharmacists, and other healthcare providers at the Cancer Institute of Northside Hospital Healthcare System and their patients with non-small-cell lung cancer. The online enduring components will also be available to the broader CCO membership.

Learning Objectives

  • Evaluate the therapeutic impact of immune checkpoint inhibitors as first-line treatment options for patients with advanced NSCLC
  • Describe the role of combination approaches to optimize immune checkpoint inhibitor efficacy and reduce treatment resistance
  • Plan treatment strategies for patients with NSCLC and disease progression on or after platinum-containing chemotherapy based on available data, treatment guidelines, and expert recommendations
  • Manage immune-related adverse events in patients with advanced NSCLC on checkpoint inhibitor therapy
  • Incorporate key principles of shared decision making to equip patients with NSCLC to participate in the treatment planning process


Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-20-990-L01-P

Type of Activity 

Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.